Calliotx
Seattle, US · 5 known investors
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment. The company's lead program is a dual-payload HER2-targeted ADC designed to deliver drug combinations to tumor cells.
Founders & leadership
PI
Piers IngramPresident, Co-Founder
JB
Jerome Boyd-KirkupChief Scientific Officer, Co-Founder
ZH
Zachary HornbyChief Executive Officer
Investors · 5
In the news
- Forward Financing $525 Million: VFN + ABS Deal Explainedfunderintel.com · 2026